Astrana Health (NASDAQ:ASTH) Posts Earnings Results, Beats Expectations By $0.39 EPS

Astrana Health (NASDAQ:ASTH) announced its quarterly earnings data on Monday. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.39, FiscalAI reports. Astrana Health had a return on equity of 5.63% and a net margin of 0.71%.The business had revenue of $950.53 million during the quarter, compared to analysts’ expectations of $930.46 million. During the same period in the previous year, the firm earned ($0.15) earnings per share. The firm’s quarterly revenue was up 42.9% compared to the same quarter last year.

Here are the key takeaways from Astrana Health’s conference call:

• Astrana closed 2025 with record results — $3.2B revenue, $205.4M adjusted EBITDA, and $104.5M free cash flow; Q4 revenue was $950.5M (up 43%) and adjusted EBITDA $52.5M (up 50%).
• 2026 guidance is for $3.8B–$4.1B revenue, $250M–$280M adjusted EBITDA, and $105M–$132.5M free cash flow, but management framed this as deliberately conservative and sensitive to Medicaid/exchange disenrollment and medical cost trends.
• The Prospect Health acquisition integration is reported as on track with >97% PCP retention and management now expects to realize the high end of the previously announced $12M–$15M annualized synergies.
• The company disclosed a material weakness in internal controls over acquisition/purchase accounting and will file a Form 12b‑25 with the 10‑K delayed into the 15‑day extension period, with remediation underway.
• Management highlighted its technology and AI-driven Astrana Care Enablement platform as a driver of operating leverage — G&A fell to 6.8% of revenue and automation/AI are expected to further improve margins and speed expansion into new markets.

Astrana Health Stock Performance

Shares of ASTH opened at $24.51 on Wednesday. The firm has a market cap of $1.38 billion, a P/E ratio of 53.28, a PEG ratio of 0.78 and a beta of 0.91. Astrana Health has a twelve month low of $18.08 and a twelve month high of $34.80. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.40 and a current ratio of 1.40. The firm’s 50 day moving average price is $23.56 and its two-hundred day moving average price is $26.24.

Wall Street Analysts Forecast Growth

ASTH has been the subject of several analyst reports. Barclays decreased their target price on Astrana Health from $36.00 to $26.00 and set an “equal weight” rating for the company in a research report on Monday, November 24th. TD Cowen decreased their price objective on shares of Astrana Health from $40.00 to $35.00 and set a “buy” rating for the company in a report on Monday, November 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrana Health in a research note on Tuesday, November 25th. Needham & Company LLC assumed coverage on shares of Astrana Health in a report on Friday, December 12th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, BTIG Research reduced their price target on shares of Astrana Health from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $35.33.

Institutional Investors Weigh In On Astrana Health

Several institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its stake in shares of Astrana Health by 323.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $115,000 after purchasing an additional 3,517 shares during the period. State of Wyoming bought a new position in shares of Astrana Health during the second quarter worth about $132,000. Los Angeles Capital Management LLC acquired a new stake in Astrana Health in the 4th quarter valued at approximately $228,000. WINTON GROUP Ltd acquired a new stake in Astrana Health in the 2nd quarter valued at approximately $233,000. Finally, Brevan Howard Capital Management LP bought a new stake in Astrana Health in the 2nd quarter valued at approximately $277,000. 52.77% of the stock is owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.